Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.38 |
| ▸ | HBB | P68871 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CYBB | P04839 | 1/20 | 0.36 |
| ▸ | NCF1 | P14598 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6763456 | 0.91 | KDM4E (0.42) | HTR1BKDM4ERAB9APOLBMEN1 | |
| SCHEMBL4890393 | 0.89 | ADRB2 (0.43) | HTR1BKDM4ERAB9APOLBMEN1 | |
| SCHEMBL31237102 | 0.83 | KDM4E (0.50) | KDM4ERAB9APOLBMEN1KMT2A | |
| SCHEMBL16322624 | 0.83 | KDM4E (0.50) | KDM4ERAB9APOLBMEN1KMT2A | |
| SCHEMBL14294338 | 0.82 | DRD2 (0.46) | HTR1BKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL22175070 | 0.81 | CHRNB2 (0.44) | HTR1BKDM4ERAB9APOLBMEN1 | |
| SCHEMBL3334395 | 0.81 | KDM4E (0.53) | KDM4ERAB9APOLBMEN1KMT2A | |
| SCHEMBL23634035 | 0.78 | KDM4E (0.50) | KDM4ERAB9APOLBMEN1KMT2A | |
| SCHEMBL29837272 | 0.78 | KDM4E (0.50) | KDM4ERAB9APOLBMEN1KMT2A | |
| SCHEMBL14269836 | 0.78 | HTR1B (0.42) | HTR1BHTR1AADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080032975-A1 | Substituted Fused Pyrroleoximes and Fused Pyrazoleoximes | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) | 2008-02-07 | — | — | US | claimed |
| US-20050059826-A1 | Substituted fused pyrroleoximes and fused pyrazoleoximes | NEUROGEN CORPORATION | 2005-03-17 | — | — | US | claimed |
| US-20040110778-A1 | Heterocyclic compounds as ligands of the GABAA receptor | YOHANNES DANIEL (US) | 2004-06-10 | — | — | US | claimed |
| US-6656941-B2 | Aryl substituted tetrahydroindazoles | NEUROGEN CORPORATION | 2003-12-02 | — | — | US | claimed |
| EP-1326831-A1 | SUBSTITUTED FUSED PYRROLEIMINES AND PYRAZOLEIMINES | NEUROGEN CORPORATION (US) | 2003-07-16 | — | — | EP | claimed |
| US-20030105081-A1 | Heterocyclic compounds as ligands of the GABAA receptor | PFIZER INC | 2003-06-05 | — | — | US | claimed |
| EP-1315703-A1 | ARYL SUBSTITUTED TETRAHYDROINDAZOLES AND THEIR USE AS LIGANDS FOR THE GABA-A RECEPTOR | NEUROGEN CORPORATION (US) | 2003-06-04 | — | — | EP | claimed |
| US-20020128236-A1 | Substituted fused pyrroleoximes and fused pyrazoleoximes | NEUROGEN CORPORATION | 2002-09-12 | — | — | US | claimed |
| US-20020055524-A1 | Novel aryl substituted tetrahydroindazoles as ligands of the GABA receptor | NEUROGEN CORPORATION | 2002-05-09 | — | — | US | claimed |
| WO-2002020492-A1 | ARYL SUBSTITUTED TETRAHYDROINDAZOLES AND THEIR USE AS LIGANDS FOR THE GABA-A RECEPTOR | NEUROGEN CORPORATION (US) | 2002-03-14 | — | — | WO | claimed |
| WO-2002020480-A1 | SUBSTITUTED FUSED PYRROLEIMINES AND PYRAZOLEIMINES | NEUROGEN CORPORATION (US) | 2002-03-14 | — | — | WO | claimed |
| US-20080032975-A1 | Substituted Fused Pyrroleoximes and Fused Pyrazoleoximes | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) | 2008-02-07 | — | — | US | disclosed |
| US-7282498-B2 | Substituted fused pyrroleoximes and fused pyrazoleoximes | NEUROGEN CORPORATION (US) | 2007-10-16 | — | — | US | disclosed |
| US-6949562-B2 | Heterocyclic compounds as ligands of the GABAA receptor | NEUROGEN CORPORATION (US) | 2005-09-27 | — | — | US | disclosed |
| US-20050059826-A1 | Substituted fused pyrroleoximes and fused pyrazoleoximes | NEUROGEN CORPORATION | 2005-03-17 | — | — | US | disclosed |
| EP-1315703-A1 | ARYL SUBSTITUTED TETRAHYDROINDAZOLES AND THEIR USE AS LIGANDS FOR THE GABA-A RECEPTOR | NEUROGEN CORPORATION (US) | 2003-06-04 | — | — | EP | disclosed |
| US-20020128236-A1 | Substituted fused pyrroleoximes and fused pyrazoleoximes | NEUROGEN CORPORATION | 2002-09-12 | — | — | US | disclosed |
| US-20020055524-A1 | Novel aryl substituted tetrahydroindazoles as ligands of the GABA receptor | NEUROGEN CORPORATION | 2002-05-09 | — | — | US | disclosed |
| WO-2002020492-A1 | ARYL SUBSTITUTED TETRAHYDROINDAZOLES AND THEIR USE AS LIGANDS FOR THE GABA-A RECEPTOR | NEUROGEN CORPORATION (US) | 2002-03-14 | — | — | WO | disclosed |
| WO-2002020480-A1 | SUBSTITUTED FUSED PYRROLEIMINES AND PYRAZOLEIMINES | NEUROGEN CORPORATION (US) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105081-A1 | Heterocyclic compounds as ligands of the GABAA receptor | GABRB1, GABRP, GABRA1 | HTR1B 198/4885KDM4E 2087/4885RAB9A 962/4885 |
| US-20050059826-A1 | Substituted fused pyrroleoximes and fused pyrazoleoximes | NPSR1, GABRE, CHRNE | HTR1B 121/4885KDM4E 986/4885RAB9A 584/4885 |
| US-20020128236-A1 | Substituted fused pyrroleoximes and fused pyrazoleoximes | HTR1A, GABRA1, GABRE | HTR1B 77/4885KDM4E 876/4885RAB9A 568/4885 |
| US-20040110778-A1 | Heterocyclic compounds as ligands of the GABAA receptor | GABRB1, GABRP, GABRA1 | HTR1B 198/4885KDM4E 2087/4885RAB9A 962/4885 |
| US-20020055524-A1 | Novel aryl substituted tetrahydroindazoles as ligands of the GABA receptor | GABRA1, GABRB1, GABRA3 | HTR1B 56/4885KDM4E 2203/4885RAB9A 860/4885 |
| US-20080032975-A1 | Substituted Fused Pyrroleoximes and Fused Pyrazoleoximes | NPSR1, GABRE, CHRNE | HTR1B 121/4885KDM4E 986/4885RAB9A 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.